New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
September 7, 2018 - The FDA announced the approval of Teva’s Cassipa (buprenorphine/naloxone) sublingual film, for the maintenance treatment of opioid dependence.
Download PDF
Return to publications
